LLY · Eli Lilly & Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.80B | - | $17.60B | $15.56B | $12.73B | - | $11.44B | $11.30B | $8.77B | - |
| Cost of Revenue | $3.58B | - | $3.01B | $2.45B | $2.22B | - | $2.17B | $2.17B | $1.67B | - |
| Gross Profit | $16.22B | - | $14.59B | $13.11B | $10.50B | - | $9.27B | $9.13B | $7.09B | - |
| R&D | $3.51B | - | $3.47B | $3.34B | $2.73B | - | $2.73B | $2.71B | $2.52B | - |
| SG&A | $2.93B | - | $2.74B | $2.75B | $2.47B | - | $2.10B | $2.12B | $1.95B | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $509.00M | - | - | - | $462.80M | - | - | - | $400.60M | - |
| Operating Income | $8.85B | - | $7.23B | $6.78B | $3.46B | - | $1.59B | $3.52B | $2.54B | - |
| Interest Expense | - | - | $179.60M | $249.00M | $179.60M | - | $124.60M | $183.60M | $179.60M | - |
| Income Tax | $1.45B | - | $1.65B | $1.12B | $696.80M | - | $618.10M | $550.20M | $293.20M | - |
| Net Income | $7.40B | - | $5.58B | $5.66B | $2.76B | - | $970.30M | $2.97B | $2.24B | - |
| EPS - Basic | $8.27 | - | $6.22 | $6.30 | $3.07 | - | $1.08 | $3.29 | $2.49 | - |
| EPS - Diluted | $8.26 | - | $6.21 | $6.29 | $3.06 | - | $1.07 | $3.28 | $2.48 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.28B | $7.27B | $9.79B | $3.38B | $3.09B | $3.27B | $3.37B | $3.22B | $2.46B | $2.82B |
| Accounts Receivable | $18.43B | $17.76B | $16.11B | $14.17B | $12.04B | $11.01B | $10.29B | $11.03B | $7.89B | $9.09B |
| Inventory | $14.53B | $13.74B | $12.18B | $11.01B | $9.31B | $7.59B | $7.46B | $6.48B | $6.10B | $5.77B |
| Accounts Payable | $5.03B | $5.38B | $4.26B | $4.08B | $3.44B | $3.23B | $2.89B | $2.92B | $2.47B | $2.60B |
| Current Assets | $54.84B | $55.63B | $62.07B | $49.85B | $41.26B | $32.74B | $31.42B | $30.20B | $25.19B | $25.73B |
| Total Assets | $116.58B | $112.48B | $114.94B | $100.92B | $89.39B | $78.71B | $75.61B | $71.87B | $63.94B | $64.01B |
| Current Liabilities | $36.63B | $35.23B | $40.14B | $39.02B | $30.07B | $28.38B | $24.67B | $27.12B | $18.60B | $27.29B |
| Long-term Debt | $39.37B | $40.87B | $40.87B | $34.18B | $34.50B | $28.53B | $29.05B | $23.73B | $24.56B | $18.32B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $31.20B | $26.54B | $23.79B | $18.27B | $15.76B | $14.19B | $14.24B | $13.56B | $12.81B | $10.77B |
| Retained Earnings | $29.51B | $24.47B | $22.25B | $17.38B | $15.10B | $13.54B | $13.63B | $13.18B | $12.55B | $10.31B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $5.33B | - | - | - | $1.67B | - | - | - | $1.17B | - |
| Investing Cash Flow | ($3.92B) | - | - | - | ($3.35B) | - | - | - | ($1.18B) | - |
| Financing Cash Flow | ($3.47B) | - | - | - | $1.38B | - | - | - | ($311.30M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 81.9% | - | 82.9% | 84.3% | 82.5% | - | 81.0% | 80.8% | 80.9% | - |
| Operating margin | 44.7% | - | 41.1% | 43.6% | 27.2% | - | 13.9% | 31.1% | 28.9% | - |
| EBITDA margin | 47.3% | - | - | - | 30.8% | - | - | - | 33.5% | - |
| Net margin | 37.4% | - | 31.7% | 36.4% | 21.7% | - | 8.5% | 26.3% | 25.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 17.7% | - | 19.7% | 21.4% | 21.5% | - | 23.9% | 24.0% | 28.8% | - |
| SG&A / Revenue | 14.8% | - | 15.6% | 17.7% | 19.4% | - | 18.4% | 18.7% | 22.3% | - |
| Effective tax rate | 16.4% | - | 22.8% | 16.5% | 20.2% | - | 38.9% | 15.6% | 11.6% | - |
| Return on assets | 6.3% | - | 4.9% | 5.6% | 3.1% | - | 1.3% | 4.1% | 3.5% | - |
| Return on equity | 23.7% | - | 23.5% | 31.0% | 17.5% | - | 6.8% | 21.9% | 17.5% | - |
| Return on invested capital | 10.5% | - | 8.6% | 10.8% | 5.5% | - | 2.2% | 8.0% | 6.0% | - |
| Liquidity | ||||||||||
| Current ratio | 1.50 | 1.58 | 1.55 | 1.28 | 1.37 | 1.15 | 1.27 | 1.11 | 1.35 | 0.94 |
| Quick ratio | 1.10 | 1.19 | 1.24 | 1.00 | 1.06 | 0.89 | 0.97 | 0.87 | 1.03 | 0.73 |
| Cash ratio | 0.14 | 0.21 | 0.24 | 0.09 | 0.10 | 0.12 | 0.14 | 0.12 | 0.13 | 0.10 |
| Leverage | ||||||||||
| Debt / Equity | 1.26 | 1.54 | 1.72 | 1.87 | 2.19 | 2.01 | 2.04 | 1.75 | 1.92 | 1.70 |
| Debt / Assets | 0.34 | 0.36 | 0.36 | 0.34 | 0.39 | 0.36 | 0.38 | 0.33 | 0.38 | 0.29 |
| Debt / EBITDA | 4.21 | - | - | - | 8.80 | - | - | - | 8.36 | - |
| Interest coverage | - | - | 40.3x | 27.2x | 19.2x | - | 12.7x | 19.2x | 14.1x | - |
| Equity multiplier | 3.74 | 4.24 | 4.83 | 5.52 | 5.67 | 5.55 | 5.31 | 5.30 | 4.99 | 5.94 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.15 | 0.15 | 0.14 | - | 0.15 | 0.16 | 0.14 | - |
| Inventory turnover | 0.25 | - | 0.25 | 0.22 | 0.24 | - | 0.29 | 0.33 | 0.27 | - |
| Days sales outstanding | 340d | - | 334d | 332d | 345d | - | 328d | 356d | 328d | - |
| Days inventory outstanding | 1483d | - | 1478d | 1642d | 1528d | - | 1254d | 1090d | 1331d | - |
| Days payable outstanding | 513d | - | 517d | 608d | 565d | - | 485d | 492d | 540d | - |
| Cash conversion cycle | 1309d | - | 1295d | 1367d | 1308d | - | 1097d | 954d | 1120d | - |
| Valuation | ||||||||||
| P / E | 111.4x | - | 122.9x | 123.9x | 269.9x | - | 828.0x | 276.0x | 313.7x | - |
| P / B | 26.4x | - | 28.8x | 38.4x | 47.2x | - | 56.3x | 60.4x | 54.9x | - |
| P / S | 41.6x | - | 39.0x | 45.1x | 58.4x | - | 70.1x | 72.4x | 80.2x | - |
| EV / EBITDA | 91.7x | - | - | - | 197.8x | - | - | - | 247.0x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 55.5% | - | 53.9% | 37.6% | 45.2% | - | 20.4% | 36.0% | 26.0% | - |
| Revenue CAGR (3y) | 41.7% | - | 36.4% | 33.8% | 17.7% | - | 19.1% | 18.8% | 8.8% | - |
| Revenue CAGR (5y) | 23.8% | - | 25.1% | 23.1% | 16.8% | - | 15.9% | 14.9% | 11.5% | - |
| Gross profit growth (YoY) | 54.4% | - | 57.4% | 43.6% | 48.1% | - | 21.3% | 40.4% | 33.0% | - |
| Operating income growth (YoY) | 156.1% | - | 355.3% | 92.7% | 36.3% | - | 271.8% | 68.4% | 65.8% | - |
| Net income growth (YoY) | 168.0% | - | 475.3% | 90.8% | 23.0% | - | - | 68.3% | 66.8% | - |
| EPS growth (YoY) | 169.9% | - | 480.4% | 91.8% | 23.4% | - | - | 68.2% | 66.4% | - |
| EPS CAGR (3y) | 77.0% | - | 56.8% | 81.6% | 13.4% | - | -4.3% | 28.9% | 18.5% | - |
| EPS CAGR (5y) | 40.9% | - | 36.1% | 32.3% | 13.8% | - | -4.8% | 17.9% | -10.5% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 97.9% | 87.0% | 67.1% | 34.7% | 23.0% | 31.8% | 26.9% | 22.6% | 14.5% | 1.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$65.18B totalReportable Segment$65.18B · 100.0%
Product / service
$150.84B totalProduct$60.96B · 40.4%
Cardiometabolic Health$33.86B · 22.5%
Mounjaro$13.65B · 9.0%
Zepbound$13.48B · 8.9%
Oncology$5.35B · 3.5%
Collaborationand Other Revenue$4.22B · 2.8%
Verzenio$3.46B · 2.3%
Immunology$2.96B · 2.0%
Trulicity$2.91B · 1.9%
Taltz$2.33B · 1.5%
Other Cardiometabolic Health$2.23B · 1.5%
Other Oncology$1.89B · 1.3%
Jardiance$1.58B · 1.0%
Neuroscience$997.00M · 0.7%
Other Immunology$631.00M · 0.4%
Other Product Total$304.00M · 0.2%
Geographic
$86.88B totalUS$43.48B · 50.0%
Non Us$21.70B · 25.0%
Europe$11.56B · 13.3%
Rest Of World$6.06B · 7.0%
JP$2.13B · 2.5%
CN$1.95B · 2.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ELI LILLY & Co against the 5 most active filers in the same SIC group.
Dividends
$6.46/share trailing 12 months · +15.4% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $1.7300 |
| Feb 13, 2026 | $1.7300 |
| Nov 14, 2025 | $1.5000 |
| Aug 15, 2025 | $1.5000 |
| May 16, 2025 | $1.5000 |
| Feb 14, 2025 | $1.5000 |
| Nov 15, 2024 | $1.3000 |
| Aug 15, 2024 | $1.3000 |
| May 15, 2024 | $1.3000 |
| Feb 14, 2024 | $1.3000 |
| Nov 14, 2023 | $1.1300 |
| Aug 14, 2023 | $1.1300 |
| May 12, 2023 | $1.1300 |
| Feb 14, 2023 | $1.1300 |
| Nov 14, 2022 | $0.9800 |
| Aug 12, 2022 | $0.9800 |
| May 13, 2022 | $0.9800 |
| Feb 14, 2022 | $0.9800 |
| Nov 12, 2021 | $0.8500 |
| Aug 12, 2021 | $0.8500 |
| May 13, 2021 | $0.8500 |
| Feb 11, 2021 | $0.8500 |
| Nov 12, 2020 | $0.7400 |
| Aug 13, 2020 | $0.7400 |